Almac Group has launched a CLIA validated next-gen sequencing test for P53 mutations, a biomarker for cancer drug discovery. Developed using the Illumina technology, the P53 test can be run on formalin fixed paraffin embedded (FFPE) samples enabling patient stratification for early phase trial enrichment studies and potential companion diagnostic development.     The test covers all coding regions and upstream regulatory regions of P53 and provides detail on specified mutations as well as sequen...